{"product_id":"novonordisk-business-model-canvas","title":"Novo Nordisk Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic playbook behind market-leading diabetes and obesity pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Novo Nordisk’s strategic playbook with our Business Model Canvas—three to five concise sentences that map value propositions, customer segments, and growth levers driving its market leadership. This detailed, downloadable canvas reveals revenue streams, partnerships, and cost drivers to inform investor decisions and strategic planning. Purchase the full, editable Word \u0026amp; Excel version to benchmark, adapt, and execute proven pharma strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJoint research with universities and institutes accelerates discovery in diabetes, obesity and rare diseases by providing access to cutting-edge science and talent pipelines that support target validation and translational studies. These collaborations de-risk early-stage assets and validate novel mechanisms through shared trials and preclinical platforms. Shared publications and participation in data consortia enhance credibility and speed to insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing and Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract manufacturing and suppliers, including API producers, biologics CMOs and device component suppliers, sustain reliable scale and quality across Novo Nordisks 10 global manufacturing sites. Securing cold-chain logistics, sterile fill-finish and device assembly capacity underpins global supply continuity and resilience. Diversified sourcing and long-term agreements covering over 70% of API and component volumes mitigate geopolitical and capacity risks and stabilize pricing and quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with public payers, private insurers and PBMs improve access and reimbursement, supporting formulary placement and patient affordability; by 2024 Novo Nordisk expanded payer deals covering millions of lives for GLP-1 therapies. Value‑based agreements tie outcomes to costs, shifting risk and lowering net spend for payers. Collaborative real‑world evidence programs (RWE) demonstrate effectiveness and adherence, aiding joint initiatives to broaden formulary inclusion and patient co‑pay assistance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Data Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliances with app developers, sensor firms, and cloud data platforms let Novo Nordisk embed connected care into diabetes and obesity treatments, enabling remote monitoring, algorithmic dose guidance, and adherence support to improve outcomes and reduce clinic visits.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegration: secure APIs for real-time CGM and pump data\u003c\/li\u003e\n\u003cli\u003eAnalytics: personalized interventions via aggregated patient data\u003c\/li\u003e\n\u003cli\u003eCo-development: faster time-to-market for companion apps and devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Professional Societies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk partners with patient advocacy groups and medical societies to shape education and policy, aligning with ADA Standards of Care 2024 to boost guideline-driven adoption; collaborations have expanded screening initiatives in regions with over 500 million adults living with diabetes. Continuous feedback loops drive patient-centric product and service design and evidence-based uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngagement: ADA Standards of Care 2024\u003c\/li\u003e\n\u003cli\u003eAwareness: targets populations amid \u0026gt;500M adults with diabetes\u003c\/li\u003e\n\u003cli\u003eOutcomes: guideline collaboration for evidence-based adoption\u003c\/li\u003e\n\u003cli\u003eDesign: patient feedback loops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic alliances de-risk; CMOs scale across 10 sites; payers cover millions \u0026gt;500M adults\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic alliances accelerate target validation and de-risk assets; CMOs and suppliers sustain scale across 10 global manufacturing sites; payer and PBM deals cover millions of lives supporting GLP-1 access; digital and patient group partnerships drive RWE and guideline adoption among \u0026gt;500M adults with diabetes.\n\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdults with diabetes\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003emillions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Novo Nordisk outlining nine BMC blocks—customer segments (diabetes, obesity, rare diseases), value propositions (innovative biologics, outcomes-driven care), channels (global healthcare partnerships), key activities (R\u0026amp;D, manufacturing), resources, partners, cost\/revenue structure, and competitive advantages with SWOT-linked insights for strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear one-page Business Model Canvas that distills Novo Nordisk’s complex pharma ecosystem—R\u0026amp;D, manufacturing, partnerships, and patient outcomes—so teams can quickly pinpoint strategic pain points, align stakeholders, and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, preclinical work and multi‑phase clinical trials form the core pipeline, with over 20 clinical programs in 2024 driving new candidates for diabetes, obesity and other chronic diseases.\u003c\/p\u003e\n\u003cp\u003eRegulatory strategy and evidence generation are embedded from first‑in‑human studies to pivotal trials to expedite approvals and market access.\u003c\/p\u003e\n\u003cp\u003eBiomarker use and digital endpoints are used to improve trial efficiency and sensitivity, reducing timelines and patient numbers.\u003c\/p\u003e\n\u003cp\u003ePortfolio management in 2024 prioritizes high‑impact chronic disease assets to maximize clinical and commercial return.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and Device Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 Novo Nordisk maintained large-scale peptide and biologic production with integrated sterile fill-finish lines as core operations. Device engineering for reusable and connected pens focused on usability, safety and patient adherence. Continuous improvement programs reduced batch deviations and improved yields, while global quality systems ensured FDA, EMA and other regulator compliance across manufacturing sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Access and Health Economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHEOR modeling and budget-impact analyses underpin payer negotiations, quantifying cost offsets and real-world value to support pricing in 2024. Outcomes-based contracts tie reimbursement to measurable patient outcomes, sharing risk between payers and Novo Nordisk. HTA submissions are adapted to local bodies such as NICE, IQWiG and HAS to meet country-specific evidence demands. Affordability programs and patient-assistance schemes expand access across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Affairs and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eField medical teams disseminate evidence and gather HCP insights responsibly, supporting clinician uptake; Novo Nordisk employed about 69,000 people in 2024, underpinning global medical reach. CME, guideline support and peer-reviewed publications build clinician confidence; real-world evidence programmes (registries and RWE studies) inform product optimisation and practice. Continuous safety monitoring and pharmacovigilance maintain clear risk–benefit profiles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField teams: global coverage, 2024 workforce ~69,000\u003c\/li\u003e\n\u003cli\u003eCME \u0026amp; publications: drive guideline adoption\u003c\/li\u003e\n\u003cli\u003eRWE studies: inform optimisation and HTA\u003c\/li\u003e\n\u003cli\u003eSafety monitoring: ongoing pharmacovigilance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercialization and lifecycle management leverages brand strategy, omnichannel promotion, and KAM to drive adoption across care settings; post-launch analytics in 2024 informed dynamic pricing and adherence programs that improved access. Indication expansions and formulation\/device updates (e.g., next‑gen injectors) extend product life while supply‑demand balancing prevented shortages in key growth markets. Novo Nordisk reported 2024 revenue of DKK 205.6 billion, underscoring commercial scale.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrand strategy: focused on premium positioning and HCP trust\u003c\/li\u003e\n\u003cli\u003eOmnichannel promotion: digital + field sales to boost reach\u003c\/li\u003e\n\u003cli\u003eKAM: drives formulary and payer adoption\u003c\/li\u003e\n\u003cli\u003eLifecycle: indication\/device updates extend ROI\u003c\/li\u003e\n\u003cli\u003eAnalytics: optimize pricing, access, adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced diabetes and obesity pipeline, integrated manufacturing, \u003cstrong\u003eDKK 205.6 bn\u003c\/strong\u003e revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery and \u0026gt;20 clinical programs in 2024 advanced diabetes, obesity and chronic‑disease candidates. Large‑scale peptide\/biologic manufacturing with integrated sterile fill‑finish and device engineering sustained supply and adherence. HEOR, RWE and outcomes‑based contracts supported market access; pharmacovigilance and field medical teams (~69,000 employees) ensured uptake. 2024 revenue DKK 205.6 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~69,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eDKK 205.6 bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Novo Nordisk Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive the identical, complete file ready for download in editable Word and Excel formats. The content, structure, and formatting match this preview exactly, with no hidden pages or placeholders. It’s ready to present, edit, and apply immediately upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatents on molecules, formulations, devices and digital algorithms secure commercial returns and market exclusivity for Novo Nordisk, while trade secrets in process chemistry and biologics manufacturing add operational durability. Freedom-to-operate analyses guide geographic and therapeutic expansion. Global patent filings are coordinated with launch sequencing across 170+ countries to optimize market access and protection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologics plants, device facilities and integrated cold-chain logistics across Europe, Americas and Asia enable scalable supply for insulin and GLP-1 products. Automation, advanced analytics and validated quality systems cut cost and variability, supporting consistent yield. Geographic diversification improves resilience to local disruption while 2023 capital expenditure of DKK 22.8bn expanded capacity to meet rising chronic-disease demand of over 530 million adults with diabetes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScientific and clinical talent at Novo Nordisk—backed by a global workforce of over 60,000—drives endocrinology, metabolism and hematology innovation; cross-functional teams accelerate decisions. Robust clinical operations and regulatory functions support efficient approvals across a 300+ trial portfolio. Data science and bioinformatics bolster discovery and RWE, supported by roughly DKK 26bn R\u0026amp;D investment (2023).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Market Access Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDeep regulatory experience with major agencies streamlines approvals and market entry, supporting rapid scale-up as the global GLP-1 market surpassed USD 70 billion in 2024; local access teams secure pricing and reimbursement across diverse HTA environments. Robust HEOR programs generate real-world evidence to underpin value narratives while compliance infrastructure limits legal and commercial risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory depth: global agency experience\u003c\/li\u003e\n\u003cli\u003eLocal access: pricing \u0026amp; reimbursement navigation\u003c\/li\u003e\n\u003cli\u003eHEOR: strong real-world evidence\u003c\/li\u003e\n\u003cli\u003eCompliance: reduced risk exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Equity and Provider Relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk’s strong reputation in diabetes and obesity builds trust, supporting Q4 2024 global sales momentum and clinician confidence after multi-year outcomes data for GLP-1 therapies.\u003c\/p\u003e\n\u003cp\u003eLongstanding ties with clinicians and health systems across 170+ countries facilitate rapid adoption; patient support services and digital programs reinforce loyalty and adherence.\u003c\/p\u003e\n\u003cp\u003eGlobal presence enables consistent standards of care and scale in manufacturing, distribution and provider partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e170+ countries presence\u003c\/li\u003e\n\u003cli\u003eRobust clinician networks\u003c\/li\u003e\n\u003cli\u003ePatient support programs drive adherence\u003c\/li\u003e\n\u003cli\u003eScale ensures consistent care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal patents and supply back GLP-1 \u0026amp; insulin in \u003cstrong\u003e170+\u003c\/strong\u003e markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatents, trade secrets and FTO analyses protect GLP-1 and insulin franchises across 170+ markets, supporting launch sequencing. Global manufacturing, cold-chain logistics and DKK 22.8bn 2023 capex ensure supply scale; workforce ~60,000 and DKK 26bn R\u0026amp;D (2023) drive innovation. Regulatory, HEOR and clinician networks underpin access as the GLP-1 market topped USD 70bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e170+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e~60,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2023)\u003c\/td\u003e\n\u003ctd\u003eDKK 26bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx (2023)\u003c\/td\u003e\n\u003ctd\u003eDKK 22.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1 market (2024)\u003c\/td\u003e\n\u003ctd\u003eUSD 70bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically Proven Outcomes in Chronic Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducts deliver meaningful reductions in disease burden—STEP 1 showed semaglutide 2.4 mg produced mean weight loss 14.9% vs 2.4% placebo at 68 weeks. Evidence spans randomized trials and real-world settings; SUSTAIN-6 showed a 26% reduction in MACE (HR 0.74). Improved adherence and persistence sustain HbA1c and weight benefits, and clear benefit-risk profiles have driven guideline inclusion for GLP-1 RAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvenient Delivery and Digital Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUser-friendly connected insulin pens and digital solutions from Novo Nordisk simplify therapy workflows and support over 537 million people living with diabetes (IDF 2021). Remote monitoring and automated reminders address the WHO-observed ~50% medication adherence gap in chronic disease, improving consistency. Secure data sharing enables collaborative care between patients and clinicians, reducing treatment friction and enhancing quality of life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Global Supply and Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRobust global manufacturing networks underpin consistent availability, supporting Novo Nordisk’s scale that helped deliver DKK 176.9 billion in 2023 revenue. Stringent quality controls and pharmacovigilance reduce variability and recalls, maintaining high batch-release standards. Integrated cold-chain logistics and inventory planning minimize disruptions across key markets. Patients and providers can trust continuity of care. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Value for Payers and Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTherapies target fewer hospitalizations and downstream complications, with the SELECT CV outcomes trial showing a 24% relative reduction in major adverse cardiovascular events and STEP trials reporting up to ~17% mean weight loss, lowering long‑term risk. HEOR analyses in 2023–2024 show improved cost‑effectiveness versus standard care in modeled lifetime QALYs, and outcomes‑based pilot contracts in 2023–2024 de‑risk payer spend while scalable support programs align with population health targets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEVP: 24% MACE reduction (SELECT)\u003c\/li\u003e\n\u003cli\u003eWeight: up to ~17% mean loss (STEP)\u003c\/li\u003e\n\u003cli\u003eHEOR: favorable cost‑effectiveness in 2023–2024 models\u003c\/li\u003e\n\u003cli\u003eRisk: outcomes‑based pilots 2023–2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Portfolio Across Care Continuum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk delivers a broad portfolio across the care continuum, from prevention and initiation to intensification and maintenance, with 2024 expansion of semaglutide indications strengthening prevention and obesity care; adjacent offerings cover obesity, rare bleeding and growth disorders while companion services bolster education and adherence and integrated solutions streamline care pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuum: prevention → maintenance\u003c\/li\u003e\n\u003cli\u003eAdjacencies: obesity, rare bleeding, growth disorders\u003c\/li\u003e\n\u003cli\u003eSupport: education, adherence programs\u003c\/li\u003e\n\u003cli\u003eIntegration: streamlined care pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e14.9%\u003c\/strong\u003e weight, \u003cstrong\u003e24%\u003c\/strong\u003e MACE cut; pens boost adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProducts cut disease burden: semaglutide 2.4 mg mean weight loss 14.9% vs 2.4% placebo (STEP1, 68 weeks) and SELECT showed 24% MACE reduction. Digital pens and services improve adherence amid WHO ~50% chronic‑disease nonadherence; 2024 saw semaglutide indication expansion. Global scale supports continuity (DKK 176.9 billion revenue 2023) and 2023–2024 HEOR models show favorable cost‑effectiveness.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTEP1 weight loss\u003c\/td\u003e\n\u003ctd\u003e14.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSELECT MACE\u003c\/td\u003e\n\u003ctd\u003e24% RR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2023)\u003c\/td\u003e\n\u003ctd\u003eDKK 176.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Engagement and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical science liaisons and structured educational programs drive evidence-based use, supporting clinicians with on-demand dosing and switching tools; Novo Nordisk reported over 70,000 employees in 2024, enabling broad clinical reach. Peer-to-peer forums and international congresses disseminate best practices and real-world data, while feedback loops from HCPs inform iterative updates to materials and digital tools. Continuous education underpins uptake of GLP-1 therapies and complex diabetes care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Adherence Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnboarding, coaching and automated reminders in Novo Nordisk patient support programs improve persistence in a field where adherence averages about 50% for chronic therapies (WHO); financial assistance schemes lower out-of-pocket barriers that otherwise drive nonadherence. Digital portals provide tracking, tips and real-time feedback while multilingual support expands reach amid an estimated 537 million adults living with diabetes globally (IDF 2021).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management with Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated KAM teams negotiate access, rebates and outcomes contracts with payers, supporting over 100 payer agreements globally; data-sharing and analytics demonstrate real-world value of GLP-1 therapies through aggregated outcomes and cost-offset analyses. Joint pilots across multiple markets test innovative payment models, while regular quarterly reviews align on performance, utilization and reimbursement adjustments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships with Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with health systems embed integrated pathways and protocols to standardize care delivery, align prescribing and referral patterns, and reduce variability in outcomes. Population health initiatives focus on high-risk cohorts—top 5% of patients who drive roughly 50% of healthcare costs—to improve outcomes and lower total cost of care. Co-developed dashboards track clinical and utilization outcomes in near real-time, while training and implementation support ensure adoption across sites.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated pathways\u003c\/li\u003e\n\u003cli\u003eHigh-risk cohort focus (top 5% → ~50% spend)\u003c\/li\u003e\n\u003cli\u003eCo-developed dashboards\u003c\/li\u003e\n\u003cli\u003eTraining \u0026amp; implementation support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity and Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration on screening, awareness and education enables earlier diagnosis and linkage to care, addressing 537 million adults living with diabetes (IDF 2021). Patient insights guide product design and targeted communication. Grants and sponsorships scale programs while transparent dialogue builds trust and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScreening partnerships → earlier diagnosis\u003c\/li\u003e\n\u003cli\u003ePatient insights → better design \u0026amp; messaging\u003c\/li\u003e\n\u003cli\u003eGrants \u0026amp; sponsorships → amplified reach\u003c\/li\u003e\n\u003cli\u003eTransparent dialogue → stronger trust \u0026amp; reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical liaisons, KAMs and patient programs raise diabetes care uptake and persistence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical liaisons, education and digital support drive clinician uptake; Novo Nordisk had \u0026gt;70,000 employees in 2024. Patient programs (onboarding, reminders, financial aid) raise persistence vs ~50% average adherence; global diabetes burden 537M (IDF 2021). KAMs manage 100+ payer agreements and outcomes pilots to prove value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Ref\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes prevalence\u003c\/td\u003e\n\u003ctd\u003e537M (IDF 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer agreements\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence benchmark\u003c\/td\u003e\n\u003ctd\u003e~50% (WHO)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales to Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField teams engage endocrinologists, primary care and specialists through targeted calls and clinical detailing to drive initiation, supported by prescription samples and patient-start programs. Account-based approaches tailor messaging for high-value accounts, aligning product value with local formulary and payer dynamics. CRM systems coordinate outreach and capture HCP insights to refine targeting and measure engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and Wholesaler Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWholesale partners ensure broad retail and specialty pharmacy availability across roughly 170 countries. Centralized inventory management plus EDI\/POS data feeds protect service levels and improve demand forecasting. Specialty channels and Novo Nordisk’s NovoCare hubs manage 2–8°C cold-chain logistics and handle prior authorization for injectable GLP-1 therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTenders and Institutional Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital and public-system tenders secure bulk volume access for Novo Nordisk, supporting scale in hospitals and national programs; in 2024 the company reported about DKK 216 billion revenue, underpinning tender competitiveness. Strict compliance with procurement and GxP rules is critical to win contracts. Value dossiers emphasize patient outcomes and budget impact, and multi-year agreements (commonly 3–5 years) stabilize supply and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and Remote Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient apps (mySugr, acquired 2020, serving over 3 million users) plus provider portals and telehealth integrations sustain continuity of care; e-prescribing accelerates initiation and refills; digital education scales reach cost-effectively; analytics and real-world data enable personalized interventions and adherence targeting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003epatient-apps: mySugr \u0026gt;3M users\u003c\/li\u003e\n\u003cli\u003etelehealth: continuity\u003c\/li\u003e\n\u003cli\u003ee-prescribing: faster starts\/refills\u003c\/li\u003e\n\u003cli\u003eanalytics: personalized care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Scientific Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCongress presentations and journal publications build Novo Nordisks credibility by creating peer-reviewed evidence; KOL engagement accelerates diffusion of innovation through endorsement and protocol change. Symposiums and hands-on workshops enable clinician skill building and therapeutic confidence, while systematic evidence dissemination supports faster market adoption and guideline inclusion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCongress abstracts and peer-reviewed journals: credibility\u003c\/li\u003e\n\u003cli\u003eKOL engagement: diffusion of innovation\u003c\/li\u003e\n\u003cli\u003eSymposiums\/workshops: skill building\u003c\/li\u003e\n\u003cli\u003eEvidence dissemination: market adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField teams \u0026amp; CRM drive HCP starts; partners secure cold-chain in ~170 countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eField teams and CRM drive HCP initiation and capture insights; account-based tactics align with local formularies. Wholesale\/specialty partners secure cold-chain across ~170 countries; 2024 revenue DKK 216 billion supports tender competitiveness. Digital tools (mySugr \u0026gt;3M users), e-prescribing and telehealth speed starts and adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField teams\/CRM\u003c\/td\u003e\n\u003ctd\u003eHCP calls, account-based\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\/specialty\u003c\/td\u003e\n\u003ctd\u003e~170 countries; cold-chain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003emySugr \u0026gt;3M users; eRx\/telehealth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with diabetes (type 1 and type 2) seek effective, convenient therapies addressing glycemic control, weight and simplicity; globally over 537 million adults live with diabetes (IDF 2021) and numbers are rising. Diverse ages, comorbidities and geographies demand tailored digital, educational and dosing support. Affordability and access remain central barriers, especially in low- and middle-income countries where insulin costs limit care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Obesity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividuals needing pharmacologic weight management and comorbidity reduction are core customers; in the US 41.9% of adults met obesity criteria (CDC 2017–2020). Semaglutide trials demonstrated sustained mean weight loss around 15% with cardiometabolic benefits. Support for lifestyle change enhances outcomes. Coverage and prior authorization remain major access hurdles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Rare Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with rare disorders include ≈400,000 people with haemophilia worldwide and growth hormone deficiency affecting roughly 1 in 3,500–10,000 children; both groups need specialized dosing, monitoring, and education. High-touch nurse-led services and home-infusion support are linked in studies to better adherence and fewer adverse events. Care is typically coordinated with hemophilia and endocrine centers of excellence to optimize outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphealthcare providers and institutions endocrinologists primary care hospitals clinics prioritize clear clinical evidence ease of administration a reliable supply chain for novo nordisk therapies while training decision tools facilitate formulary adoption workflow integration. institutional buyers demand predictable contractible pricing service levels to manage budget procurement cycles.\u003e\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEndocrinologists: evidence and outcomes-driven\u003c\/li\u003e\n\u003cli\u003ePrimary care: ease of use, training support\u003c\/li\u003e\n\u003cli\u003eHospitals\/clinics: reliable supply, predictable pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phealthcare\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and health systems — including public and private insurers, PBMs (CVS Caremark, Express Scripts, OptumRx control about 80% of US prescriptions), and national health services — prioritize cost-effectiveness and measurable outcomes. They require robust real-world evidence and contracting flexibility to enable access. Population-health alignment drives faster adoption of Novo Nordisk therapies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost-effectiveness \u0026amp; outcomes\u003c\/li\u003e\n\u003cli\u003eRobust RWE \u0026amp; flexible contracts\u003c\/li\u003e\n\u003cli\u003ePBM market concentration ~80%\u003c\/li\u003e\n\u003cli\u003ePopulation-health alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated GLP-1 and insulin care with digital support meets surging diabetes and specialty demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with diabetes and obesity seek effective, convenient GLP-1\/insulin therapies with digital support; \u0026gt;537 million adults have diabetes (IDF 2021) and demand grows. Rare-disease and specialty endocrine\/haemophilia patients need high-touch dosing, monitoring and home services. Providers, payers and PBMs (control ~80% US scripts in 2024) prioritize outcomes, cost-effectiveness and predictable supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;537M adults (IDF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003e~80% US scripts (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and Clinical Trial Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, clinical trials and regulatory activities drive both fixed infrastructure and variable per-patient costs; Novo Nordisk reported R\u0026amp;D spend of DKK 25.9 billion in 2024, reflecting that trend. Increasing trial complexity and composite endpoints have materially raised budgets and timelines. Global programs require extensive site networks and monitoring, and post-marketing safety and outcomes studies add ongoing, often multi-year, spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologics production, device assembly and cold-chain logistics drive high unit costs; in 2024 Novo Nordisk ramped manufacturing investments—about DKK 30bn—reflecting capacity expansions and specialized cold-chain networks. GMP, validation and batch testing add recurring quality costs and regulatory overheads. Large-capex plants push up-front expenses, while incremental yield improvements gradually reduce COGS over product lifecycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Medical Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eField forces, omnichannel campaigns and education drive adoption, with significant spend on sales and marketing to support global launches; in 2024 Novo Nordisk reported revenue above DKK 200 billion, underscoring scale-backed promotional investment. Medical engagement, clinical publications and congress activity require dedicated budgets and external funding. Launch costs peak around regulatory approvals and new indications, compressing cashflow. Ongoing compliance, certification and training add recurring overhead to SG\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Access and Patient Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHEOR development, tendering and contracting are material cost drivers in market access and patient support, funding evidence generation and pricing negotiations in 2024. Assistance programs and hubs absorb ongoing costs to boost adherence and affordability, while investment in data infrastructure enables outcomes tracking. Market localization raises implementation complexity and cost per market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR, tenders, contracts: core access costs\u003c\/li\u003e\n\u003cli\u003eSupport hubs: adherence \u0026amp; affordability spend\u003c\/li\u003e\n\u003cli\u003eData platforms: outcomes measurement\u003c\/li\u003e\n\u003cli\u003eLocalization: multiplies market-specific costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and Administrative costs cover corporate functions, IT, legal and compliance that sustain Novo Nordisk operations; IT and cybersecurity investments rise as data privacy demands increase and EU CSRD reporting began phasing in 2024. ESG reporting and assurance add ongoing resource demands, while FX hedging and global insurance programs manage international risk exposure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate functions: ongoing operating overhead\u003c\/li\u003e\n\u003cli\u003eIT \u0026amp; cybersecurity: increased investment for data privacy\u003c\/li\u003e\n\u003cli\u003eESG \u0026amp; reporting: new 2024 compliance burden\u003c\/li\u003e\n\u003cli\u003eFX \u0026amp; insurance: global risk mitigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D \u003cstrong\u003e25.9bn\u003c\/strong\u003e, mfg \u003cstrong\u003e~30bn\u003c\/strong\u003e; revenue \u0026gt; \u003cstrong\u003e200bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, trials and regulatory work drive fixed and per-patient costs (R\u0026amp;D DKK 25.9bn in 2024). Biologics manufacturing, devices and cold-chain raise unit COGS; manufacturing investments ~DKK 30bn in 2024. Sales, market access and support hubs create steady SG\u0026amp;A and access spend as global launches and HEOR\/tenders increase market-specific costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 25.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing investment\u003c\/td\u003e\n\u003ctd\u003e~DKK 30bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;DKK 200bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription product sales drive Novo Nordisk’s core revenue, with diabetes and obesity therapies (notably GLP-1s), haemophilia and growth treatments accounting for the bulk of 2024 sales of DKK 291.9 billion; volume growth and rising market share in GLP-1 therapies propelled topline expansion. Geographic expansion, especially in the US and China, added incremental sales, while realized revenue was shaped by pricing and product mix shifts across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevice and Connected Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from injection devices and digital companions complements medicine sales, with device bundles increasing patient stickiness and differentiating Novo Nordisk in diabetes and obesity care.\u003c\/p\u003e\n\u003cp\u003eData-enabled services create pathways for premium subscription tiers and value-based contracts tied to outcomes.\u003c\/p\u003e\n\u003cp\u003eRegular upgrades, consumable replacements and device lifecycle sales generate recurring revenue and higher customer lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Tender Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMulti-year hospital and government contracts give Novo Nordisk predictable, recurring volumes and helped shore up supply planning amid the 2024 surge in GLP-1 demand.\u003c\/p\u003e\n\u003cp\u003eThese tenders often accept tighter unit margins in exchange for volume certainty, supporting capital allocation and manufacturing scale-up.\u003c\/p\u003e\n\u003cp\u003ePerformance clauses in contracts can trigger bonuses for delivery\/efficacy or penalties for shortfalls, aligning incentives with payers.\u003c\/p\u003e\n\u003cp\u003eRegulatory approvals and expanded indications in 2024 opened add-on volumes from institutional channels. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and collaborations deliver upfronts, milestones and ongoing royalties from partnered assets, and in 2024 these deals continued to complement Novo Nordisk’s product revenues. Co-development agreements spread clinical and commercial risk and lower capex, while in-licensing fills pipeline gaps to sustain long-term growth. Data‑sharing agreements and real‑world evidence partnerships generate ancillary income and strategic insights.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts: near‑term cash\u003c\/li\u003e\n\u003cli\u003eMilestones: de‑risk value\u003c\/li\u003e\n\u003cli\u003eRoyalties: recurring income\u003c\/li\u003e\n\u003cli\u003eCo‑development: cost\/risk share\u003c\/li\u003e\n\u003cli\u003eIn‑licensing: pipeline fill\u003c\/li\u003e\n\u003cli\u003eData‑sharing: ancillary revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and Indication Expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeographic launches and new indication approvals extend product life for Novo Nordisk by opening treatment markets beyond diabetes, notably obesity and NASH, while label expansions increase eligible patient pools and drive recurring prescriptions.\u003c\/p\u003e\n\u003cp\u003eReimbursement wins accelerate uptake by lowering patient cost barriers and enabling formulary placement; lifecycle management—formulation tweaks, delivery improvements and indication stacking—sustains growth across regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue diversification\u003c\/li\u003e\n\u003cli\u003eLabel-driven patient pool expansion\u003c\/li\u003e\n\u003cli\u003eReimbursement = faster uptake\u003c\/li\u003e\n\u003cli\u003eLifecycle management sustains long-term growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 led medicines, devices and licensing drove \u003cstrong\u003eDKK 291.9 bn\u003c\/strong\u003e in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrescription medicines (diabetes, obesity, haemophilia, growth) drove DKK 291.9 billion in 2024 sales, led by GLP-1 volume and US\/China expansion. Devices and digital companions add recurring revenue and higher lifetime value. Licensing, milestones and royalties provide upfronts and ongoing income. Multi‑year tenders and performance contracts stabilize volumes and align payer incentives.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003eDKK 291.9 bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription medicines\u003c\/td\u003e\n\u003ctd\u003eMajority of sales (GLP‑1 growth)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices \u0026amp; services\u003c\/td\u003e\n\u003ctd\u003eRecurring, retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/partners\u003c\/td\u003e\n\u003ctd\u003eUpfronts, milestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098304287068,"sku":"novonordisk-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/novonordisk-business-model-canvas.png?v=1781802268","url":"https:\/\/pestel-analysis.com\/products\/novonordisk-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}